Consequently to the pilot trial which showedan increased SMN protein level in healthy carriers as well in SMA patients[26], four clinical trials with VPA and carnitine(to avoid the possible toxicity of the drug) have been started[27]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.